Study 19: Long-term exposure to treatment
•
Overall, 18 (13%) of 136 patients had received olaparib for 5 years or more: 11 of these patients had
BRCAm (15% of 74 patients with BRCAm) and seven were in the BRCAwt subgroup (12% of 57 patients
with BRCAwt).
0
5
10
15
20
25
30
35
40
45
50
≥1
≥2
≥3
≥4
≥5
≥6
Patients on olaparib (%)
Number of years on olaparib
13%
33%
14%
19%
14%
5%
Overall study population
BRCA
m subgroup
BRCA
wt subgroup
15%
12%
Courtesy of Dr. Ledermann
Who are these patients?
